Update on the Genetic Pathogenesis and Treatment of Psoriatic Arthritis

MENG Li,WANG Pei-guang,ZHANG Xue-jun
DOI: https://doi.org/10.3760/cma.j.issn.1673-4173.2013.04.009
2013-01-01
International Journal of Dermatology and Venereology
Abstract:Psoriatic arthritis is a chronic inflammatory disorder mainly affecting joints.Recent studies have revealed that the development of psoriatic arthritis is associa with many susceptible genes or loci,including interleukin-23 receptor (IL-23R),IL-12B,HLA-Cw6,TRAF3IP2,NO,FBXL19 and PSMA6-NFKBIA nearby,and likely associated with some genes or single nucleotide polymorphisms (SNPs),such as IL-23A,TNIP1,tumor necrosis factor*-857T,LCE3C-LCE3Bdel variant,REL gene and IL-13.Multiple biological agents targeting some key immune molecules or cells in the pathogenesis of psoriatic arthritis have been used to its treatment with a favorable efficacy and safety,including cytokine inhibitors (infliximab,etanercept,adalimumab,golimumab,ustekinumab),phosphodiesterase inhibitors (apremilast),T-cell inhibitors (abatacept),and B lymphocyte-depleting agent (rituximab).
What problem does this paper attempt to address?